Paratek Pharmaceuticals Announces Change to Time of 2020 Annual Meeting of Stockholders
BOSTON, May 29, 2020 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development […]
Avenue Therapeutics to Host Virtual Annual Meeting of Stockholders
NEW YORK, May 29, 2020 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development […]
Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020
HAMILTON, Bermuda, May 29, 2020 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, […]
TSX News -
RioCan Real Estate Investment Trust Schedules Date of Second Quarter 2020 Earnings Release, Conference Call and Webcast
TORONTO, May 29, 2020 (GLOBE NEWSWIRE) — RioCan Real Estate Investment Trust (“RioCan”) (TSX: REI.UN) today announced that it is […]
TRACON Pharmaceuticals Highlights Updated Envafolimab Results in MSI-H/dMMR Colorectal Cancer and Results from Clinical Trial of Opdivo and Yervoy Combination Therapy in Undifferentiated Pleomorphic Sarcoma Conducted by Alliance for Clinical Trials in Oncology
Undifferentiated Pleomorphic Sarcoma is the Major Sarcoma Subtype to be Enrolled inTRACON’s Pivotal ENVASARC Trial of Envafolimab as a Single Agent […]
TG Therapeutics Announces Final Results of the GENUINE Phase 3 Study Evaluating Ublituximab plus Ibrutinib in Previously Treated High-Risk Chronic Lymphocytic Leukemia at the 56th American Society of Clinical Oncology Annual Meeting
The addition of ublituximab to ibrutinib significantly improved PFS, ORR, CR rate, and increased rates of uMRD compared with ibrutinib […]
Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046
SAN DIEGO, May 29, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation […]
Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
Phase 3 data presented in oral presentation during the ASCO20 Virtual Scientific Program, with simultaneous publication in the New England […]
Mondelēz International Participates in JDE Peet’s IPO; Retains Significant Stake
Mondelēz International contributed to JDE Peet’s successful listing on Euronext AmsterdamCompany will retain two board seats at the global coffee […]
Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting
REDIRECT is a Registration-directed Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with […]
